IRLAB Therapeutics AB has announced a delay in patient recruitment for its ongoing Phase 2b clinical trial evaluating pirepemat as a potential treatment for Parkinson's disease. The study, designed to assess the efficacy and safety of pirepemat, is now expected to be fully enrolled by the end of 2023, pushing the anticipated top-line results to the first half of 2024.
The Phase 2b trial is being conducted across 39 sites in five European countries. Currently, 28 of these sites are active and progressing as planned. IRLAB is implementing strategies to address the slower-than-expected enrollment rate, focusing on enhancing patient screening and recruitment efforts.
"Activities are continuously underway to support patient screening and recruitment to allow the study to be completed on time," the company stated in a press release.
In parallel with the pirepemat study, IRLAB's preclinical programs are advancing according to their established timelines. Furthermore, the company anticipates presenting additional data from the completed Phase 2b study of mesdopetam in the first half of 2023. Mesdopetam is another investigational drug being developed by IRLAB for Parkinson's disease.
Parkinson's disease is a progressive neurodegenerative disorder affecting millions worldwide. Current treatments primarily manage symptoms, highlighting the need for novel therapies that can address the underlying disease mechanisms. IRLAB Therapeutics is focused on developing innovative treatments to improve the lives of individuals living with Parkinson's disease.
